Gsk (GSK) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $8.3 billion.
- Gsk's Long-Term Deferred Tax rose 184.73% to $8.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 billion, marking a year-over-year increase of 184.73%. This contributed to the annual value of $8.6 billion for FY2024, which is 1479.85% up from last year.
- Gsk's Long-Term Deferred Tax amounted to $8.3 billion in Q3 2025, which was up 184.73% from $8.8 billion recorded in Q2 2025.
- In the past 5 years, Gsk's Long-Term Deferred Tax ranged from a high of $8.8 billion in Q2 2025 and a low of $421.3 million during Q1 2022
- Moreover, its 5-year median value for Long-Term Deferred Tax was $7.1 billion (2023), whereas its average is $6.9 billion.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first tumbled by 9291.38% in 2022, then skyrocketed by 151842.39% in 2023.
- Quarter analysis of 5 years shows Gsk's Long-Term Deferred Tax stood at $7.0 billion in 2021, then decreased by 5.65% to $6.6 billion in 2022, then increased by 13.13% to $7.5 billion in 2023, then increased by 15.52% to $8.7 billion in 2024, then fell by 4.06% to $8.3 billion in 2025.
- Its Long-Term Deferred Tax stands at $8.3 billion for Q3 2025, versus $8.8 billion for Q2 2025 and $8.1 billion for Q1 2025.